Not yet recruiting
Diagnosis of Women With ANOCA
NCT07802457· NHS Greater Glasgow and Clyde· Source
Contact: Clare Dolan
Recruiting
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
NCT07768189· Phase 3· Corbus Pharmaceuticals Inc.· Source
Contact: Clinical Study Coordinator
Not yet recruiting
Exercise Therapy for Women With ANOCA
NCT07733986· NHS Greater Glasgow and Clyde· Source
Contact: Clare Dolan
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843· Phase 1· Eli Lilly and Company· Source
Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109· Phase 3· Nuvalent Inc.· Source
Contact: Jason Adhikaree, MBBS, Ph.D. (principal investigator)
Recruiting
Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
NCT06762769· Phase 2· University College, London· Source
Contact: Dean Smith
Recruiting
Identifying the Causes and Risk Factors of Pulmonary Exacerbations in Cystic Fibrosis
NCT06940531· Alexander Horsley· Source
Contact: Helen Barr
Recruiting
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT06499285· Phase 3· Takeda· Source
Contact: Jennifer Byrne (principal investigator)
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556· Phase 3· Hoffmann-La Roche· Source
Recruiting
Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma
NCT05635162· Phase 2· University College, London· Source
Contact: Mark Bishton
Active, not recruiting
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626· Phase 3· LeonaBio· Source
Contact: Sarah Khan
Recruiting
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239· Phase 3· Hoffmann-La Roche· Source
Recruiting
RCT of Implantable Defibrillators in Patients With Non Ischemic Cardiomyopathy, Scar and Severe Systolic Heart Failure
NCT05568069· University Hospital Southampton NHS Foundation Trust· Source
Contact: Jenny Chuen, Dr
Active, not recruiting
Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression
NCT04920708· Phase 2· Royal Marsden NHS Foundation Trust· Source
Active, not recruiting
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT05501886· Phase 3· Celcuity Inc· Source
Recruiting
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
NCT05498428· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
NCT05306340· Phase 3· Genentech, Inc.· Source
Recruiting
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
NCT04892173· Phase 3· Johnson & Johnson Enterprise Innovation Inc.· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
NCT04712097· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)
NCT04546620· Phase 2· University Hospital Southampton NHS Foundation Trust· Source
Active, not recruiting
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
NCT04717414· Phase 3· Celgene· Source
Active, not recruiting
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04408638· Phase 3· Hoffmann-La Roche· Source
Recruiting
Methods of T Cell Depletion Trial (MoTD)
NCT04888741· Phase 2· University of Birmingham· Source
Contact: MoTD Trial
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
NCT04576455· Phase 2· Hoffmann-La Roche· Source
Recruiting
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
NCT04625907· Phase 1/2· University of Birmingham· Source
Contact: Ivo Hennig
Recruiting
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
NCT04307576· Phase 3· Mats Heyman· Source
Contact: Gerardo Errico, M.D. (principal investigator)
Active, not recruiting
A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT
NCT04217278· Phase 2/3· University of Birmingham· Source
Recruiting
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
NCT04116502· Phase 3· University of Birmingham· Source
Contact: Natalia Morelli
Active, not recruiting
A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome
NCT03899337· Phase 2· University of Birmingham· Source
Active, not recruiting
Stereotactic Body Radiotherapy for the Treatment of OPD
NCT03256981· Phase 2/3· Institute of Cancer Research, United Kingdom· Source
Active, not recruiting
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
NCT03148418· Phase 3· Hoffmann-La Roche· Source
Recruiting
The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)
NCT03562169· Phase 3· University of Leeds· Source
Contact: Jenny Byrne
Recruiting
Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer
NCT03150576· Phase 2/3· Cambridge University Hospitals NHS Foundation Trust· Source
Contact: Stephen Chan (principal investigator)
Active, not recruiting
Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)
NCT02215265· Phase 3· Lisette Nixon· Source
Active, not recruiting
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
NCT02375204· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)
NCT04116047· Phase 3· University of Birmingham· Source
Active, not recruiting
Prostate Advances in Comparative Evidence
NCT01584258· Phase 3· Royal Marsden NHS Foundation Trust· Source
Active, not recruiting
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
NCT00268476· Phase 2/3· Medical Research Council· Source